(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 90.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.36%.
Prothena Public Co's revenue in 2026 is $9,684,000.On average, 9 Wall Street analysts forecast PRTA's revenue for 2026 to be $6,315,147,118, with the lowest PRTA revenue forecast at $5,275,632,236, and the highest PRTA revenue forecast at $8,481,386,314. On average, 8 Wall Street analysts forecast PRTA's revenue for 2027 to be $1,449,614,539, with the lowest PRTA revenue forecast at $0, and the highest PRTA revenue forecast at $5,652,463,110.
In 2028, PRTA is forecast to generate $5,550,180,444 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $8,608,970,481.